Aastrom Biosciences Inc. (ASTM) Profile

Profile for Aastrom Biosciences Inc. (ASTM)


Business Description: Aastrom Biosciences, Inc. is regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.

Address:	24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, MI, 48106
Telephone:	(734) 418-4400	Website:	www.aastrom.com
Facsimile:	(734) 665-0485	Email:	mail@aastrom.com


Details

CEO:	Timothy M. Mayleben
Employees:	54	Market Cap:	70.7 m
Issue Type:	CS
Auditor:	PricewaterhouseCoopers LLP
Last Audit:	Unqualified
Indices:	Biotechnology


Industry Classifications

Sector:	Healthcare	CIK:	0000887359
Industry:	Drugs
Sub-Industry:	Biotechnology
NAICS:	Biological Product (except Diagnostic) Manufacturing (325414)
SIC:	Biological Products, Except Diagnostic Substances (2836)

Tags for Aastrom Biosciences Inc.

Research stocks or mutual funds related to Aastrom Biosciences Inc. by keywords or tags. Find companies that have a similar focus to ASTM. The keywords below have been associated to ASTM by either user submission or electronic means.

stem cells information guided tissue regeneration king report on corporate governance history of embryonic stem cell research cloning stem cells human embryonic stem cell stem cell research paper tissue repair neural stem cell stem cell product tissue engineering stem cells china stem cell biology stem cells diabetes embryonic stem cells Biological Products embryo stem cell research save stem cells stem cell tech corporate governance practices stem cell information corporate governance issues define corporate governance board of directors role stem cell news stem cell research debate stem cell research and diabetes investments corporate governance disclosure embryo stem cell board of directors governance directors duties stem cell research articles for stem cell research stem cells therapy Drugs corporate governance hong kong stem cell transplantation stem cell board of directors compensation bone graft dental bone grafting mouse embryonic stem cells embryo stem cells bone substitute stem cell legislation stem cell research legislation stem cell spinal cord injury stem cell research ethics Healthcare

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.